A new clinical trial, CKD-bioMatch (an important part of the PRIME-CKD project) has been initiated, aiming to improve treatment for patients with progressive chronic kidney disease (CKD).This initiative represents a major step toward bringing precision medicine from the lab to the clinic, using real biological signals to guide treatment decisions.

The CKD-bioMatch trial is recruiting 125 patients with progressive CKD. Patients from Denmark, Germany, Spain, United Kingdom and Sweden are being included for the trial that will run for 3 years

At INCLIVA, the Health Research Institute of Hospital Clínico Universitario de Valencia, recruitment is progressing rapidly.

Dr Jose Luis Górriz, Principal Investigator at INCLIVA Valencia, emphasises the significance of the Project: “Our goal is to move toward a model of care in which treatment decisions in chronic kidney disease are informed not only by traditional clinical parameters but also by validated biological signals. Biomarkers may help us identify patients at higher risk of progression and guide more personalised therapeutic strategies.”

Coordinator of PRIME-CKD Hiddo L. Heerspink (UMCG, The Netherlands) shares the excitement about the start  of  the CKD-bioMatch trial:

“The enrolment of the first patients into the CKD-bioMatch trial marks an important step towards a better understanding how to personalize the treatment of CKD” says Hiddo L. Heerspink, PRIME-CKD coordinator. “This study pioneers a personalized medicine approach by using biological markers (biomarkers) to guide treatment, ensuring that the right drug reaches the right patient at the right time.”

What this may mean in practice
If successful, CKD-bioMatch could help patients receive effective therapy sooner. By identifying non-responders early, clinicians may prevent avoidable disease progression and reduce the likelihood of severe complications such as dialysis.

For healthcare systems, biomarker-guided therapy has the potential to improve treatment efficiency by focusing resources on therapies that offer measurable benefit. This could support future decision-making for reimbursement, guideline development and long-term kidney-health strategies.

PRIME-CKD – 9/3/2025